Kodiak Sciences in Focus After Upgrade by J.P. Morgan!
Reading Time: 2 minutes
Kodiak Sciences is a biopharmaceutical company based in Palo Alto, California, specializing in the development of therapies for retinal diseases. At the core is the company's proprietary antibody-polymer conjugate technology, which aims to develop medications that remain effective in the eye longer than conventional treatments. The leading drug candidate, Tarcocimab Tedromer, is currently in late-stage clinical trials for diabetic retinopathy and wet age-related macular degeneration. Additionally, Kodiak is working on other preparations for the...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
